Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study

Schizophrenia Research

Volumn 99, Issue 1-3, 2008, Pages 23-28

  Rejas, Javier ^a   Bobes, Julio ^b   Arango, Celso ^c   Aranda, Pedro ^d   Carmena, Rafael ^e   Garcia Garcia, Margarida ^f  

^a PFIZER INC   (United States)

^b UNIVERSITY OF OVIEDO   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f Project Management Department   (Spain)

Author keywords

Antipsychotic treatment; Concordance; Metabolic syndrome; Modified NCEP ATP III criteria; NCEP ATP III; Outpatients; Schizophrenia

Indexed keywords

AMISULPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE SEVERITY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; METABOLIC SYNDROME X; OUTPATIENT; POST HOC ANALYSIS; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTRIGLYCERIDEMIA; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SPAIN; WAIST-HIP RATIO;

EID: 39249083919     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.10.015     Document Type: Article

References (21)

1. Alberti K.G., Zimmet P., Shaw J., and IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
2. Alegría E., Cordero A., Laclaustra M., Grima A., León M., Casasnovas J.A., Luengo E., del Río A., Ferreira I., and MESYAS study group. Prevalencia del síndrome metabólico en población laboral española: registro MESYAS. Rev. Esp. Cardiol. 58 (2005) 797-806
3. Bobes J., Arango C., Aranda P., Carmena R., García-García M., Rejas J., and CLAMORS Study Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr. Res. 90 (2007) 162-173
4. Bobes J., Rejas J., Garcia-Garcia M., Rico-Villademoros F., García-Portilla M.P., Fernández I., Hernández G., and EIRE Study Group. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr. Res. 62 (2003) 77-88
5. Cheal K.L., Abbasi F., Lamendola C., McLaughlin T., Reaven G.M., and Ford E.S. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 53 (2004) 1195-1200
6. Cohn T., Prud′homme D., Streiner D., Kameh H., and Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry 49 (2004) 753-760
7. Correll C., Frederickson A., Kane J., and Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J. Clin. Psychiatry 67 4 (2006) 575-583
8. Enger C., Weatherby L., Reynolds R.F., Glasser D.B., and Walker A.M. Serious cardiovascular events and mortality among patients with schizophrenia. J. of Nerv. Ment. Dis. 192 (2004) 19-27
9. Heiskanen T., Niskanen L., Lyytikainen R., Saarinen P.I., and Hintikka J. Metabolic syndrome in patients with schizophrenia. J. Clin. Psychiatry 64 (2003) 575-579
10. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
11. Lamberti J.S., Crilly J.F., Maharaj K., Olson D., Wiener K., Dvorin S., Costea G.O., Bushey M.P., and Dietz M.B. Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J. Clin. Psychiatry 65 (2004) 702-706
12. Landis J.R., and Koch G.C. The measurement of observer agreement for categorical data. Biometrics 33 (1977) 159-174
13. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., and Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80 (2005) 19-32
14. National Institute of Health. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
15. Pérez F., Mora G., and Díez J. Epidemiología. Impacto del síndrome metabólico en la salud pública en España. Med. Clin., Monogr. 7 (2006) 8-12 (Barc)
16. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107 (2003) 391-397
17. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., Isles C., Macfarlane P.W., Packard C.J., Cobbe S.M., and Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
18. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., and Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 159 (2002) 561-566
19. Sicras, A., Rejas, J., Navarro, R., Serrat, J., Blanca, M., 2006. Prevalence of metabolic syndrome in patients with bipolar disorder: a cross-sectional assessment of a Health Management Organization in Spain. Value in Health 9 (6), A309.
20. Wirshing D. Schizophrenia and obesity: impact of antipsychotic medications. J. Clin. Psychiatry 65 Suppl 18 (2004) 13-26
21. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L., and INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 9438 (2004) 937-952